Quick adme quote
Inflammasome Whitepaper
Overcoming Selectivity and Safety Challenges in Drug Discovery
Discover how cutting-edge inflammasome biology, advanced cellular models, and validated screening assays can accelerate your inflammatory and neurodegenerative drug programs.
Chronic inflammation drives a wide range of human diseases—and inflammasomes sit at the center of this process. As interest in NLRP3 and other inflammasome targets accelerates, drug developers face a critical challenge: proving efficacy, selectivity, and safety early in the discovery pipeline.
This whitepaper reveals the latest insights in inflammasome biology and highlights the key pitfalls that can derail promising candidates. You’ll learn how to select the right in vitro models, choose meaningful readouts, and leverage advanced systems like primary macrophages, iPSC-derived microglia, and organotypic brain slices.
See how Concept Life Sciences’ validated inflammasome assays can help you de-risk your program, generate translational data, and confidently progress your therapeutics toward clinical trials.
Download hte whitepaper to learn:
Why inflammasomes are powerful, but complex therapeutic targets across inflammatory and neurodegenerative diseases
How to overcome common selectivity and toxicity challenges in inflammasome drug development
Which in vitro models best predict translational success—from THP-1 screens to human macrophages and CNS-relevant microglia
The essential readouts needed to confirm mechanism of action, potency, and pyroptosis inhibition
How a validated, end-to-end assay suite can accelerate lead optimization and reduce clinical attrition
Complete the form to download the whitepaper.
You will be able to download hte pdf once the the form is submitted.